RESUMEN
Here, we present the unique case of a 51-year-old German patient with multiple myeloma excreting Ascaris lumbricoides in his stool five weeks after allogeneic hematopoietic stem cell transplantation. Stool analysis remained negative for the presence of eggs, and there was no eosinophilia in the peripheral blood at any time around stem cell transplantation. The patient was commenced on a three-day treatment with mebendazole, which was well tolerated. No serious interactions with the concomitant post-transplant medication or negative effects on the hematopoiesis were observed, and the myeloma still is in complete remission. To our knowledge, this is the first report on excretion of A lumbricoides in the context of allogeneic stem cell transplantation. The case is remarkable with view to the fact that the parasite has supposedly survived all courses of myeloma treatment including autologous and allogeneic conditioning. Parasitosis with A lumbricoides has a worldwide prevalence of about a billion and is extremely rare in northern Europe. Possibly the patient got infected during a trip to Egypt years before multiple myeloma was diagnosed.
Asunto(s)
Ascariasis/diagnóstico , Heces/parasitología , Trasplante de Células Madre Hematopoyéticas , Mebendazol/uso terapéutico , Animales , Ascaris lumbricoides , Egipto , Humanos , Masculino , Persona de Mediana Edad , Mieloma Múltiple/parasitología , Mieloma Múltiple/terapia , Recuento de Huevos de Parásitos , Trasplante de Células Madre , Acondicionamiento Pretrasplante , Trasplante HomólogoRESUMEN
Strongyloides stercoralis chronic infection is frequently subclinical and thus under-recognized, although its increasing prevalence in nonendemic regions has implications for immunocompromised hosts. We present a 75-year-old male with stage II multiple myeloma who presented with relapse of Strongyloides infection after initial treatment, negative surveillance testing, and subsequent resumption of chemotherapy for his multiple myeloma. The optimal regimen for secondary prophylaxis against recurrent infections is unknown. Secondary prophylaxis should be considered for patients who recur and/or remain at high risk of recurrence because of ongoing immunosuppression. We implemented a prophylactic regimen of ivermectin 200 mcg/kg once monthly. In addition, improved laboratory assays for strongyloidiasis are needed to aid with diagnosis, monitoring of treatment response, and early detection of relapse.
Asunto(s)
Colitis/parasitología , Mieloma Múltiple/parasitología , Estrongiloidiasis/diagnóstico , Anciano , Animales , Anticuerpos Antihelmínticos/sangre , Antígenos Helmínticos/sangre , Colitis/complicaciones , Colitis/tratamiento farmacológico , Humanos , Intestinos/parasitología , Ivermectina/uso terapéutico , Masculino , Mieloma Múltiple/complicaciones , Mieloma Múltiple/tratamiento farmacológico , Strongyloides stercoralis , Estrongiloidiasis/complicaciones , Estrongiloidiasis/tratamiento farmacológicoAsunto(s)
Filariasis Linfática/diagnóstico , Mieloma Múltiple/diagnóstico , Células Plasmáticas/parasitología , Anciano , Animales , Filariasis Linfática/parasitología , Humanos , Masculino , Microfilarias/aislamiento & purificación , Mieloma Múltiple/parasitología , Wuchereria bancrofti/aislamiento & purificaciónAsunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Leishmaniasis Visceral/patología , Mieloma Múltiple , Trasplante de Células Madre de Sangre Periférica , Anciano , Autoinjertos , Ciclofosfamida/administración & dosificación , Dexametasona/administración & dosificación , Humanos , Leishmaniasis Visceral/sangre , Lenalidomida , Masculino , Mieloma Múltiple/sangre , Mieloma Múltiple/parasitología , Mieloma Múltiple/patología , Mieloma Múltiple/terapia , Talidomida/administración & dosificación , Talidomida/análogos & derivadosRESUMEN
The spectrum of kidney disease-associated monoclonal immunoglobulin and plasma cell malignancies is remarkably broad and encompasses nearly all nephropathologic entities. Multiple myeloma with kidney impairment at presentation is a medical emergency since the recovery of kidney function is associated with survival benefits. In most cases, kidney impairment may be the first clinical manifestation of malignant plasma cell dyscrasias like multiple myeloma and light chain amyloidosis. Multiple myeloma per se cannot be considered a main risk factor for developing acute kidney injury following intravascular administration of iodinated contrast media. The risk is increased by comorbidities such as chronic kidney disease, diabetes, hypercalcemia, dehydration, and use of nephrotoxic drugs. Before the administration of contrast media, the current recommended laboratory tests for assessing kidney function are serum creatinine measurement and the estimation of glomerular filtration rate by using the CKD-EPI equation. The assessment of Bence Jones proteinuria is unnecessary for evaluating the risk of kidney failure in patients with multiple myeloma, since this test cannot be considered a surrogate biomarker of kidney function.
Asunto(s)
Medios de Contraste/efectos adversos , Mieloma Múltiple/parasitología , Insuficiencia Renal/inducido químicamente , Insuficiencia Renal/fisiopatología , Insuficiencia Renal/orina , Amiloidosis/orina , Animales , Proteína de Bence Jones/orina , Medios de Contraste/uso terapéutico , Tasa de Filtración Glomerular/efectos de los fármacos , Humanos , Cadenas Ligeras de Inmunoglobulina/orina , Proteinuria/inducido químicamente , Proteinuria/fisiopatología , Proteinuria/orinaRESUMEN
Infectious complications remain a major problem after allogeneic hematopoietic stem cell transplant (HSCT). Specifically Toxoplasma gondii infection is a life-threatening condition in immunocompromised patients. In order to highlight the difficulties in obtaining an early and definitive diagnosis, we report three cases of toxoplasmosis after HSCT for hematologic malignancies: two cases of T. gondii retinochoroiditis, and one case of encephalitis. All patients had unrelated donors and received antithymocyte globulin; none had received trimethoprim/sulfamethoxazole prophylaxis. Toxoplasmosis occurred early post-transplant and diagnosis was obtained by real-time PCR. In one case, the correct diagnosis could only be established by PCR analysis of a retinal biopsy specimen. Rapid diagnosis--by invasive approaches--and an immediate onset of antiparasite treatment are crucial to avoid disseminated and often lethal Toxoplasma infections in the post-transplant period. Post-transplant prevention strategies and treatment to control advanced infection in this setting are discussed.